[Form 4] Septerna, Inc. Insider Trading Activity
Septerna, Inc. insider Daniel D. Long, the company's SVP of Drug Discovery, received a grant of stock options allowing him to purchase 30,000 shares of Septerna common stock at an exercise price of $11.70 per share.
The option award was recorded with a transaction date of 08/07/2025, carries an expiration date of 08/06/2035, and vests in monthly installments equal to 1/48th of the total award beginning August 1, 2025, subject to continued service. The filing shows the reporting person holds 30,000 options following the transaction and lists the ownership form as direct.
Septerna, Inc. il dirigente interno Daniel D. Long, vicepresidente senior per la scoperta di farmaci (SVP), ha ricevuto un'assegnazione di opzioni su azioni che gli consente di acquistare 30,000 azioni ordinarie di Septerna al prezzo di esercizio di $11.70 per azione.
L'assegnazione delle opzioni 猫 registrata con data di operazione 08/07/2025, ha scadenza il 08/06/2035 e matura in rate mensili pari a 1/48 del totale a partire dal 1 agosto 2025, subordinata alla continuazione del servizio. Il deposito indica che la persona segnalante detiene 30,000 opzioni dopo l'operazione e dichiara la forma di propriet脿 come diretta.
Septerna, Inc. el directivo interno Daniel D. Long, vicepresidente senior de Drug Discovery, recibi贸 una concesi贸n de opciones sobre acciones que le permiten comprar 30,000 acciones ordinarias de Septerna a un precio de ejercicio de $11.70 por acci贸n.
La adjudicaci贸n figura con fecha de operaci贸n 08/07/2025, vence el 08/06/2035 y se consolida en cuotas mensuales iguales a 1/48 del total a partir del 1 de agosto de 2025, sujeto a la continuidad del servicio. La presentaci贸n muestra que la persona informante posee 30,000 opciones tras la transacci贸n y registra la forma de propiedad como directa.
Septerna, Inc. 雮措秬鞛� Daniel D. Long(鞁犾暯 氚滉荡 攵�氍� SVP)鞚� 30,000欤茧ゼ 欤茧嫻 頄夓偓 臧�瓴� $11.70鞐� 毵れ垬頃� 靾� 鞛堧姅 鞀ろ啞 鞓奠厴鞚� 攵�鞐皼鞎橃姷雼堧嫟.
鞓奠厴 攵�鞐姅 瓯半灅鞚检潉 08/07/2025搿� 旮办灛頄堨溂氅� 毵岆鞚检潃 08/06/2035鞚搓碃, 2025雲� 8鞗� 1鞚�攵�韯� 鞝勳泊鞚� 1/48鞌� 毵れ洈 氩犾姢韺呺悩氅� 瓿勳啀 攴茧臧� 臁瓣贝鞛呺媹雼�. 鞝滌稖靹滊鞐� 霐半ゴ氅� 氤搓碃鞚胳潃 瓯半灅 頉� 30,000臧滌潣 鞓奠厴鞚� 氤挫湢頃橁碃 鞛堨溂氅� 靻岇湢 順曧儨電� 歆侅爲 氤挫湢搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Septerna, Inc. l'initi茅 Daniel D. Long, vice鈥憄r茅sident senior en Drug Discovery, a re莽u une attribution d'options sur actions lui permettant d'acheter 30,000 actions ordinaires de Septerna au prix d'exercice de $11.70 par action.
L'attribution est enregistr茅e avec une date de transaction du 08/07/2025, expire le 08/06/2035 et se acquiert par mensualit茅s 茅gales 脿 1/48 du total 脿 partir du 1er ao没t 2025, sous r茅serve de la poursuite du service. Le d茅p么t indique que la personne d茅clarante d茅tient 30,000 options apr猫s la transaction et pr茅cise que la forme de propri茅t茅 est directe.
Septerna, Inc.-Insider Daniel D. Long, Senior Vice President f眉r Drug Discovery, erhielt eine Gew盲hrung von Aktienoptionen, die ihm den Kauf von 30,000 Septerna-Stammaktien zum Aus眉bungspreis von $11.70 je Aktie erm枚glichen.
Die Optionszuteilung ist mit dem Transaktionsdatum 08/07/2025 erfasst, l盲uft am 08/06/2035 ab und wird in monatlichen Raten f盲llig, die jeweils 1/48 des Gesamtbetrags entsprechen, beginnend am 1. August 2025, vorbehaltlich fortgesetzter Dienstzeit. Die Meldung zeigt, dass die meldepflichtige Person nach der Transaktion 30,000 Optionen h盲lt und die Eigentumsform als direkt angibt.
- Clear, time-based vesting schedule: 1/48th monthly vesting beginning 08/01/2025 supports retention incentives
- Ten-year term to expiration: expiration date 08/06/2035 aligns with long-term alignment between executive and shareholders
- Exercise price disclosed: exercise price is explicitly listed as $11.70, providing transparency on strike terms
- None.
Insights
TL;DR: Routine officer option grant; limited immediate market impact but aligns executive incentives long-term.
The Form 4 documents a standard option grant to an executive: 30,000 options at a $11.70 exercise price with a 10-year contractual horizon to 08/06/2035 and a time-based vesting schedule of 1/48th monthly beginning 08/01/2025. From a securities perspective, this is a compensation-related issuance that typically dilutes over time as vested options are exercised; however, the filing alone does not quantify any immediate dilution relative to outstanding share count or indicate material change to financials.
TL;DR: Governance-wise this is a standard retention-style grant with clear vesting; no red flags in the disclosure itself.
The disclosure identifies the reporting person as an officer (SVP, Drug Discovery) and specifies a monthly vesting cadence (1/48th) tied to continued service, which is consistent with long-term incentive practices. The terms shown鈥攅xercise price of $11.70, 30,000 option quantity, and expiration in 2035鈥攁re explicit. The filing does not show any acceleration clauses or unusual transfer/indirect ownership arrangements.
Septerna, Inc. il dirigente interno Daniel D. Long, vicepresidente senior per la scoperta di farmaci (SVP), ha ricevuto un'assegnazione di opzioni su azioni che gli consente di acquistare 30,000 azioni ordinarie di Septerna al prezzo di esercizio di $11.70 per azione.
L'assegnazione delle opzioni 猫 registrata con data di operazione 08/07/2025, ha scadenza il 08/06/2035 e matura in rate mensili pari a 1/48 del totale a partire dal 1 agosto 2025, subordinata alla continuazione del servizio. Il deposito indica che la persona segnalante detiene 30,000 opzioni dopo l'operazione e dichiara la forma di propriet脿 come diretta.
Septerna, Inc. el directivo interno Daniel D. Long, vicepresidente senior de Drug Discovery, recibi贸 una concesi贸n de opciones sobre acciones que le permiten comprar 30,000 acciones ordinarias de Septerna a un precio de ejercicio de $11.70 por acci贸n.
La adjudicaci贸n figura con fecha de operaci贸n 08/07/2025, vence el 08/06/2035 y se consolida en cuotas mensuales iguales a 1/48 del total a partir del 1 de agosto de 2025, sujeto a la continuidad del servicio. La presentaci贸n muestra que la persona informante posee 30,000 opciones tras la transacci贸n y registra la forma de propiedad como directa.
Septerna, Inc. 雮措秬鞛� Daniel D. Long(鞁犾暯 氚滉荡 攵�氍� SVP)鞚� 30,000欤茧ゼ 欤茧嫻 頄夓偓 臧�瓴� $11.70鞐� 毵れ垬頃� 靾� 鞛堧姅 鞀ろ啞 鞓奠厴鞚� 攵�鞐皼鞎橃姷雼堧嫟.
鞓奠厴 攵�鞐姅 瓯半灅鞚检潉 08/07/2025搿� 旮办灛頄堨溂氅� 毵岆鞚检潃 08/06/2035鞚搓碃, 2025雲� 8鞗� 1鞚�攵�韯� 鞝勳泊鞚� 1/48鞌� 毵れ洈 氩犾姢韺呺悩氅� 瓿勳啀 攴茧臧� 臁瓣贝鞛呺媹雼�. 鞝滌稖靹滊鞐� 霐半ゴ氅� 氤搓碃鞚胳潃 瓯半灅 頉� 30,000臧滌潣 鞓奠厴鞚� 氤挫湢頃橁碃 鞛堨溂氅� 靻岇湢 順曧儨電� 歆侅爲 氤挫湢搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Septerna, Inc. l'initi茅 Daniel D. Long, vice鈥憄r茅sident senior en Drug Discovery, a re莽u une attribution d'options sur actions lui permettant d'acheter 30,000 actions ordinaires de Septerna au prix d'exercice de $11.70 par action.
L'attribution est enregistr茅e avec une date de transaction du 08/07/2025, expire le 08/06/2035 et se acquiert par mensualit茅s 茅gales 脿 1/48 du total 脿 partir du 1er ao没t 2025, sous r茅serve de la poursuite du service. Le d茅p么t indique que la personne d茅clarante d茅tient 30,000 options apr猫s la transaction et pr茅cise que la forme de propri茅t茅 est directe.
Septerna, Inc.-Insider Daniel D. Long, Senior Vice President f眉r Drug Discovery, erhielt eine Gew盲hrung von Aktienoptionen, die ihm den Kauf von 30,000 Septerna-Stammaktien zum Aus眉bungspreis von $11.70 je Aktie erm枚glichen.
Die Optionszuteilung ist mit dem Transaktionsdatum 08/07/2025 erfasst, l盲uft am 08/06/2035 ab und wird in monatlichen Raten f盲llig, die jeweils 1/48 des Gesamtbetrags entsprechen, beginnend am 1. August 2025, vorbehaltlich fortgesetzter Dienstzeit. Die Meldung zeigt, dass die meldepflichtige Person nach der Transaktion 30,000 Optionen h盲lt und die Eigentumsform als direkt angibt.
FAQ
What transaction is reported in the Septerna (SEPN) Form 4?
Who is the reporting person on the Form 4 for SEPN?
When does the option vest and when does it expire?
How many derivative securities does Daniel Long beneficially own after the transaction?
What was the transaction date reported on the Form 4?
